Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Massachusetts General Hospital
Revolution Medicines, Inc.
Shanghai Fengxian District Central Hospital
SpeciCare
MultiVir, Inc.
National Cancer Institute (NCI)
Julius-Maximilians University